Iqvia 3Q Profit, Rev Rise on Higher Demand

Dow Jones

2025/10/28

By Rob Curran

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.

Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.

Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.

IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.

IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 28, 2025 07:50 ET (11:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2578956596"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578956596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578956596?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578956596","market":"nz","top_or_hot":-1,"title":"Iqvia 3Q Profit, Rev Rise on Higher Demand","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iqvia 3Q Profit, Rev Rise on Higher Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIqvia 3Q Profit, Rev Rise on Higher Demand\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-28 19:50</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1261432733.SGD","symbol_name":"Fidelity World A-ACC-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578956596","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578956596","pubTimestamp":1761652200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4588":"碎股","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4121":"生命科学工具和服务","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4585":"ETF&股票定投概念","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BK4530":"医药外包概念","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","IQV":"艾昆纬","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H"},"translate_title":"Iqvia第三季度利润、营业额因需求增加而上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n\n\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n\n\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n\n\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n\n\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n\n\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 07:50 ET (11:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}